Urotensin II Receptor on Preoperative Biopsy is Associated with Upstaging and Upgrading in Prostate Cancer

Overview

Journal Future Oncol

Specialty Oncology

Date 2015 Sep 19

PMID 26381851

Citations 12

Authors

Ottavio de Cobelli

Carlo Buonerba

Daniela Terracciano

Danilo Bottero

Giuseppe Lucarelli

Pierluigi Bove

Vincenzo Altieri

Ioman Coman

Sisto Perdona

Gaetano Facchini

Massimiliano Berretta

Giuseppe Di Lorenzo

Paolo Grieco

Ettore Novellino

Renato Franco

Michele Caraglia

Claudia Manini

Vincenzo Mirone

Sabino De Placido

Guru Sonpavde

Matteo Ferro

Affiliations

Soon will be listed here.

Abstract

Aim: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients.

Methods: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry.

Results: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55-68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23-100.48).

Conclusions: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.

Citing Articles

The Effect of Local Renin Angiotensin System in the Common Types of Cancer.

Almutlaq M, Alamro A, Alamri H, Alghamdi A, Barhoumi T Front Endocrinol (Lausanne). 2021; 12:736361.

PMID: 34539580 PMC: 8446618. DOI: 10.3389/fendo.2021.736361.

Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82.

Dodla P, Bhoopalan V, Khoo S, Miranti C, Sridhar S BMC Cancer. 2020; 20(1):1211.

PMID: 33298014 PMC: 7724878. DOI: 10.1186/s12885-020-07675-7.

Cribriform pattern does not have a significant impact in Gleason Score ≥7/ISUP Grade ≥2 prostate cancers submitted to radical prostatectomy.

Flammia S, Frisenda M, Maggi M, Magliocca F, Ciardi A, Panebianco V Medicine (Baltimore). 2020; 99(38):e22156.

PMID: 32957339 PMC: 7505347. DOI: 10.1097/MD.0000000000022156.

Analysis of key genes reveal lysine demethylase 5B promotes prostate cancer progression.

Yang Z, Xu J, Fang D, Ke J Oncol Lett. 2020; 20(4):62.

PMID: 32863895 PMC: 7436301. DOI: 10.3892/ol.2020.11923.

XPC exon15 Lys939Gln variant increase susceptibility to prostate adenocarcinoma: Evidence based on 4306 patients and 4779 controls.

Qin F, Gao S, Xu K, Su Q, Zhang Z, Shi L Medicine (Baltimore). 2020; 99(28):e21160.

PMID: 32664151 PMC: 7360297. DOI: 10.1097/MD.0000000000021160.

References

Tao Z, Shi A, Wang K, Zhang W . Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015; 19(5):805-12. View

Caster J, Falchook A, Hendrix L, Chen R . Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients. Int J Radiat Oncol Biol Phys. 2015; 92(2):244-51. DOI: 10.1016/j.ijrobp.2015.01.051. View

Oh J, Park S, Lee S, Hong S, Lee S, Choe G . The use of exome genotyping to predict pathological Gleason score upgrade after radical prostatectomy in low-risk prostate cancer patients. PLoS One. 2014; 9(8):e104146. PMC: 4122442. DOI: 10.1371/journal.pone.0104146. View

Corcoran N, Hong M, Casey R, Hurtado-Coll A, Peters J, Harewood L . Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int. 2011; 108(8 Pt 2):E202-10. DOI: 10.1111/j.1464-410X.2011.10119.x. View

Hwang I, Lim D, Jeong Y, Park S, Noh J, Kwon D . Upgrading and upstaging of low-risk prostate cancer among Korean patients: a multicenter study. Asian J Androl. 2015; 17(5):811-4. PMC: 4577596. DOI: 10.4103/1008-682X.143751. View

Hegde J, Chen M, Mulkern R, Fennessy F, DAmico A, Tempany C . Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 85(2):e101-7. PMC: 3545042. DOI: 10.1016/j.ijrobp.2012.08.032. View

Jain S, Loblaw A, Vesprini D, Zhang L, Kattan M, Mamedov A . Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. J Urol. 2015; 194(1):79-84. DOI: 10.1016/j.juro.2015.01.102. View

Chun F, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T . Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol. 2006; 49(5):820-6. DOI: 10.1016/j.eururo.2005.11.007. View

Truong M, Slezak J, Lin C, Iremashvili V, Sado M, Razmaria A . Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013; 119(22):3992-4002. PMC: 4880351. DOI: 10.1002/cncr.28303. View

10.

Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S . Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2014; 33(3):272-7. DOI: 10.1200/JCO.2014.55.1192. View

11.

Faria E, Chapin B, Muller R, Machado R, Reis R, Matin S . Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. Urology. 2015; 86(1):10-5. DOI: 10.1016/j.urology.2015.03.012. View

12.

Terracciano D, Bruzzese D, Ferro M, Mazzarella C, Di Lorenzo G, Altieri V . Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading. Prostate. 2011; 72(1):100-7. DOI: 10.1002/pros.21411. View

13.

Balakan O, Kalender M, Suner A, Cengiz B, Oztuzcu S, Bayraktar R . The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer. Med Sci Monit. 2014; 20:1419-25. PMC: 4138065. DOI: 10.12659/MSM.890459. View

14.

Muralidhar V, Dinh K, Mahal B, Ziehr D, Chen Y, Viswanathan V . Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015; 33(7):330.e19-25. DOI: 10.1016/j.urolonc.2015.03.010. View

15.

Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y . Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides. 2003; 24(2):301-6. DOI: 10.1016/s0196-9781(03)00039-1. View

16.

Eifler J, Feng Z, Lin B, Partin M, Humphreys E, Han M . An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2012; 111(1):22-9. PMC: 3876476. DOI: 10.1111/j.1464-410X.2012.11324.x. View

17.

Chen W, Mao K, Liu Z, Dinh-Xuan A . The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review). Oncol Lett. 2014; 8(5):1907-1911. PMC: 4186560. DOI: 10.3892/ol.2014.2471. View

18.

van Soest R, de Morree E, Shen L, Tannock I, Eisenberger M, de Wit R . Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur Urol. 2013; 66(2):330-6. DOI: 10.1016/j.eururo.2013.08.007. View

19.

Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M . Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. J Cell Biochem. 2010; 112(1):341-53. DOI: 10.1002/jcb.22933. View

20.

Franco R, Zappavigna S, Gigantino V, Luce A, Cantile M, Cerrone M . Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. J Exp Clin Cancer Res. 2014; 33:48. PMC: 4061920. DOI: 10.1186/1756-9966-33-48. View